Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.

@article{Michna2011SubcutaneousMF,
  title={Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.},
  author={Edward Michna and E. Richard Blonsky and Seth L. Schulman and Evan L Tzanis and Amy L. Manley and Haiying Zhang and Shrividya S Iyer and Bruce P Randazzo},
  journal={The journal of pain : official journal of the American Pain Society},
  year={2011},
  volume={12 5},
  pages={554-62}
}
UNLABELLED Methylnaltrexone is effective for opioid-induced constipation (OIC) in advanced illness patients. This 4-week, double-blind, randomized, placebo-controlled study investigated the effect of subcutaneous methylnaltrexone on OIC in patients receiving opioids for chronic, nonmalignant pain. Patients (N = 460) received subcutaneous methylnaltrexone 12 mg once daily (QD) or every other day (alternating with placebo) compared with placebo. Assessments included bowel movement count, time of… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…